Home > Insider Trading > Filing (0001062993-22-009836)

Filing Details

Accession Number:: 0001062993-22-009836
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-04-05 19:54:18
Reporting Period:: 2022-04-01

Accepted Time:: 2022-04-05 19:54:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1177648	Enanta Pharmaceuticals Inc	ENTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1646976	Nathalie Adda	C/O Enanta Pharmaceuticals, Inc. 500 Arsenal Street Watertown MA 02472	Sr. Vp & Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-04-01	16,000	$31.42	50,982	No	4	M	Direct
Common Stock	Acquisiton	2022-04-01	31,664	$30.00	82,646	No	4	M	Direct
Common Stock	Acquisiton	2022-04-01	2,895	$48.52	85,541	No	4	M	Direct
Common Stock	Disposition	2022-04-01	8,299	$70.75	77,242	No	4	S	Direct
Common Stock	Disposition	2022-04-01	42,260	$71.32	34,982	No	4	S	Direct
Common Stock	Acquisiton	2022-04-04	6,285	$48.52	41,267	No	4	M	Direct
Common Stock	Acquisiton	2022-04-04	9,625	$43.57	50,892	No	4	M	Direct
Common Stock	Acquisiton	2022-04-04	16,875	$63.35	67,767	No	4	M	Direct
Common Stock	Disposition	2022-04-04	2,500	$70.56	65,267	No	4	S	Direct
Common Stock	Disposition	2022-04-04	18,076	$71.71	47,191	No	4	S	Direct
Common Stock	Disposition	2022-04-04	3,200	$72.65	43,991	No	4	S	Direct
Common Stock	Disposition	2022-04-04	9,009	$73.42	34,982	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2022-04-01	16,000	$0.00	16,000	$31.42
Common Stock	Stock Option (Right to Buy)	Disposition	2022-04-01	31,664	$0.00	31,664	$30.00
Common Stock	Stock Option (Right to Buy)	Disposition	2022-04-01	2,895	$0.00	2,895	$48.52
Common Stock	Stock Option (Right to Buy)	Disposition	2022-04-04	6,285	$0.00	6,285	$48.52
Common Stock	Stock Option (Right to Buy)	Disposition	2022-04-04	9,625	$0.00	9,625	$43.57
Common Stock	Stock Option (Right to Buy)	Disposition	2022-04-04	16,875	$0.00	16,875	$63.35

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2025-11-20	No	4	M	Direct
0	2026-11-18	No	4	M	Direct
6,285	2027-11-17	No	4	M	Direct
0	2027-11-17	No	4	M	Direct
21,175	2030-11-20	No	4	M	Direct
13,125	2029-11-18	No	4	M	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in December 2021 in contemplation of her previously announced retirement plan.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.12 to $71.00, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.02 to $72.00, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.06 to $70.99, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $71.00 to $71.99, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $72.00 to $72.99, inclusive.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $73.00 to $73.91, inclusive.
100% of the shares subject to the option are fully vested and exercisable.
The option, representing a right to purchase a total of 30,800 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 20, 2020).
The option, representing a right to purchase a total of 30,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 18, 2019).